{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:09:10Z","timestamp":1787620150804,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jgar.2020.01.027","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T19:53:37Z","timestamp":1582055617000},"page":"68-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Systematic review and meta-analysis to estimate the antibacterial treatment effect of nitrofurantoin for a non-inferiority trial in uncomplicated urinary tract infection"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8829-7088","authenticated-orcid":false,"given":"Fanny S.","family":"Mitrani-Gold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Raychaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapna","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2020.01.027_bib0005","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2020.01.027_bib0010","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrurol.2010.190","article-title":"The epidemiology of urinary tract infection","volume":"7","author":"Foxman","year":"2010","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.jgar.2020.01.027_bib0015","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1067\/mda.2003.7","article-title":"Epidemiology of urinary tract infections: incidence, morbidity, and economic costs","volume":"49","author":"Foxman","year":"2003","journal-title":"Dis Mon"},{"key":"10.1016\/j.jgar.2020.01.027_bib0020","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/MOU.0b013e32832ae18c","article-title":"An update on uncomplicated urinary tract infections in women","volume":"19","author":"Wagenlehner","year":"2009","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.jgar.2020.01.027_bib0025","series-title":"Draft guidance for industry. Uncomplicated urinary tract infections: developing drugs for treatment","author":"US Food and Drug Administration (FDA)","year":"2018"},{"key":"10.1016\/j.jgar.2020.01.027_bib0030","unstructured":"Bonkat G, Pickard R, Bartoletti R, Cai T, Bruy\u00e8re F, Geerlings SE, et al. Urological infections. European Association of Urology guidelines 2018. Arnhem, The Netherlands: EAU Guidelines Office. http:\/\/uroweb.org\/guideline\/urological-infections\/ [Accessed January 2018]."},{"key":"10.1016\/j.jgar.2020.01.027_bib0035","series-title":"Guidelines on urological infections","author":"Grabe","year":"2015"},{"key":"10.1016\/j.jgar.2020.01.027_bib0040","series-title":"Guidance for industry. Non-inferiority clinical trials to establish effectiveness","author":"US Food and Drug Administration (FDA)","year":"2016"},{"key":"10.1016\/j.jgar.2020.01.027_bib0045","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/jac\/dkv147","article-title":"Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials","volume":"70","author":"Huttner","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2020.01.027_bib0050","series-title":"Guidance for industry. Complicated urinary tract infections: developing drugs for treatment","author":"US Food and Drug Administration (FDA)","year":"2018"},{"key":"10.1016\/j.jgar.2020.01.027_bib0055","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1128\/AAC.01257-13","article-title":"A systematic review and meta-analysis of antimicrobial treatment effect estimation in complicated urinary tract infection","volume":"57","author":"Singh","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.01.027_bib0060","unstructured":"European Medicines Agency (EMA). Committee for Medicinal Products for Human Use. Addendum to \u2018Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections\u2019 to address indication-specific clinical data. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003417.pdf [Accessed January 2017]."},{"issue":"Suppl. 2","key":"10.1016\/j.jgar.2020.01.027_bib0065","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0924-8579(03)00229-2","article-title":"Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO\u00b7SENS Study","volume":"22","author":"Kahlmeter","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2020.01.027_bib0070","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1086\/422145","article-title":"Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed approach to empirical therapy","volume":"39","author":"Hooton","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2020.01.027_bib0075","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.medmal.2011.07.005","article-title":"French results of the ARESC Study: clinical aspects and epidemiology of the antimicrobial resistance in female patients with cystitis. Implications for empiric therapy","volume":"42","author":"Neuzillet","year":"2012","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.jgar.2020.01.027_bib0080","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1128\/AAC.06060-11","article-title":"In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010","volume":"56","author":"Sanchez","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.01.027_bib0085","series-title":"Antibiotic resistance threats in the United States, 2013","author":"US Department of Health and Human Services","year":"2013"},{"key":"10.1016\/j.jgar.2020.01.027_bib0090","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1086\/652237","article-title":"The 10 \u00d7 \u201920 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020","volume":"50","author":"Infectious Diseases Society of America","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2020.01.027_bib0095","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1128\/AAC.01277-13","article-title":"The FDA reboot of antibiotic development","volume":"57","author":"Shlaes","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.01.027_bib0100","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanations and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jgar.2020.01.027_bib0105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1741-7015-6-13","article-title":"Helping editors, peer reviewers and authors improve the clarity, completeness, and transparency of reporting health research","volume":"6","author":"Moher","year":"2008","journal-title":"BMC Med"},{"key":"10.1016\/j.jgar.2020.01.027_bib0110","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jgar.2020.01.027_bib0115","series-title":"Cochrane handbook for systematic reviews of interventions version 5.1.0","first-page":"187","article-title":"Assessing risk of bias in included studies","author":"Higgins","year":"2011"},{"key":"10.1016\/j.jgar.2020.01.027_bib0120","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/jama.1995.03520250057034","article-title":"Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women","volume":"273","author":"Hooton","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2020.01.027_bib0125","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1742-1241.1988.tb08585.x","article-title":"Comparison of mictral with amoxycillin, trimethoprim and nitrofurantoin in the treatment of acute cystitis","volume":"42","author":"Lightstone","year":"1988","journal-title":"Br J Clin Pract"},{"key":"10.1016\/j.jgar.2020.01.027_bib0130","first-page":"729","article-title":"Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women","volume":"52","author":"Christiaens","year":"2002","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.jgar.2020.01.027_bib0135","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1001\/archinte.167.20.2207","article-title":"Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women","volume":"167","author":"Gupta","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jgar.2020.01.027_bib0140","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1002\/sim.1091","article-title":"Approaches to heterogeneity in meta-analysis","volume":"20","author":"Petitti","year":"2001","journal-title":"Stat Med"},{"key":"10.1016\/j.jgar.2020.01.027_bib0145","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/ije\/dyn065","article-title":"Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation","volume":"37","author":"Patsopoulos","year":"2008","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jgar.2020.01.027_bib0150","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/ije\/dyn204","article-title":"Commentary: heterogeneity in meta-analysis should be expected and appropriately quantified","volume":"37","author":"Higgins","year":"2008","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jgar.2020.01.027_bib0155","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/1740774512465495","article-title":"Meta-analysis of clinical trial safety data in a drug development program: answers to frequently asked questions","volume":"10","author":"Berlin","year":"2013","journal-title":"Clin Trials"},{"key":"10.1016\/j.jgar.2020.01.027_bib0160","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jgar.2020.01.027_bib0165","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cct.2006.04.004","article-title":"Random-effects model for meta-analysis of clinical trials: an update","volume":"28","author":"DerSimonian","year":"2007","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jgar.2020.01.027_bib0170","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/S0149-2918(00)86734-X","article-title":"Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection","volume":"21","author":"Stein","year":"1999","journal-title":"Clin Ther"},{"issue":"Suppl. A","key":"10.1016\/j.jgar.2020.01.027_bib0175","first-page":"67","article-title":"A trial comparing low-dose, short-course ciprofloxacin and standard 7-day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection","volume":"43","author":"Iravani","year":"1999","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. A","key":"10.1016\/j.jgar.2020.01.027_bib0180","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/jac\/33.suppl_A.121","article-title":"Nitrofurantoin modified release versus trimethoprim or co-trimoxazole in the treatment of uncomplicated urinary tract infection in general practice","volume":"33","author":"Spencer","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2020.01.027_bib0185","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF01871127","article-title":"Fosfomycin trometamol in a single dose versus seven days nitrofurantoin in the treatment of acute uncomplicated urinary tract infections in women","volume":"15","author":"Van Pienbroek","year":"1993","journal-title":"Pharm World Sci"},{"key":"10.1016\/j.jgar.2020.01.027_bib0190","first-page":"663","article-title":"A comparative study of pipemidic acid and nitrofurantoin in the treatment of uncomplicated urinary tract infections","volume":"72","author":"Meyer","year":"1987","journal-title":"S Afr Med J"},{"key":"10.1016\/j.jgar.2020.01.027_bib0195","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/02813430601183074","article-title":"Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: the LUTIW Project","volume":"25","author":"Ferry","year":"2007","journal-title":"Scand J Prim Health Care"},{"issue":"Suppl. 4","key":"10.1016\/j.jgar.2020.01.027_bib0200","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2165\/00003495-199100424-00005","article-title":"Single dose oral administration of cefixime 400mg in the treatment of acute uncomplicated cystitis and gonorrhoea","volume":"42","author":"Asbach","year":"1991","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2020.01.027_bib0205","first-page":"90","article-title":"Treatment of urinary infection with a single dose of co-trimoxazole compared with a single dose of amoxicillin and a placebo [in French]","volume":"112","author":"Dubi","year":"1982","journal-title":"Schweiz Med Wochenschr"},{"key":"10.1016\/j.jgar.2020.01.027_bib0210","series-title":"Infectious diseases","article-title":"Miscellaneous agents","author":"Huttner","year":"2017"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716520300308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716520300308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:55:10Z","timestamp":1761990910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716520300308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":42,"alternative-id":["S2213716520300308"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2020.01.027","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review and meta-analysis to estimate the antibacterial treatment effect of nitrofurantoin for a non-inferiority trial in uncomplicated urinary tract infection","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2020.01.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 GlaxoSmithKline plc. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}